Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Wednesday 03 February 2021 8:25 am

Covid antibodies last at least six months after infection

By: Poppy Wood

Add as a preferred source on Google
Instituto Vital Brasil Develops Medication Against the Coronavirus (COVID - 19) Using Horses's Plasma
Almost all people had antibodies three months after infection, while 88 per cent did after six months

Coronavirus antibodies last for at least six months after infection for almost all people who have had the virus, according to a new study.

A wide-scale study, by medical database UK Biobank, found that 99 per cent of participants who tested positive for coronavirus retained antibodies for at least three months, while 88 per cent did so for at least six months.

The study lasted for six months. It is not currently known how long Covid antibodies last in total.

The research also suggested 8.8 per cent of the UK’s population had been infected by December.

London had the highest level of antibodies of any region in the country, with around 12 per cent of people across the capital previously having contracted the virus by December last year. As many as 14.7 per cent of people living in east London had antibodies at that time.

Professor Naomi Allen, chief scientist with UK Biobank, said: “Although we cannot be certain how this relates to immunity, the results suggest that people may be protected against subsequent infection for at least six months following natural infection.

“More prolonged follow-up will allow us to determine how long such protection is likely to last.”

Read more

Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument

For the six-month period between the end of May and December 2020, UK Biobank collected monthly blood samples and data on potential symptoms from 20,200 participants and their adult children and grandchildren.

There was no gender difference in antibody levels, but the proportion of participants with detectable antibodies was highest in younger people (13.5 per cent among those under-30) and lowest in the elderly (6.7 per cent among those over-70).

The most common symptom associated with having antibodies was a loss of sense of taste and smell, which was reported by 43 per cent of people who had previously been infected with the virus.

Around a quarter of people with antibodies had contracted the virus completely asymptomatically, while 40 per cent did not have any of the three major tell-tale signs — a fever, persistent cough or loss of sense of taste or smell.

However, scientists warned that people with antibodies may still be able to pass the virus on to others.

Professor Sir Rory Collins, UK Biobank principal investigator said this meant it was “important to maintain the social distancing and the lockdown measures in line with the government guidance”.

Read more

Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Tech

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • Housebuilding giants hit with £4.5bn lawsuit for allegedly overcharging buyers

  • A meeting with the breakfast king of Mayfair

  • Brewdog chief executive quits after only one year

  • As it happened: Stocks jump on defence and metals boost; Oil on track to shed a fifth on US-Iran peace hopes

More from City PM

  • Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • Over Half of Consumers Will Pay More for Brands That Are Transparent About AI Data Use, New Usercentrics Research Finds

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Stockbroker boom down under boosts CMC Markets share price

    Investing
    London Stock Exchange digital tickers displaying real-time stock prices and market updates in a bustling financial setting
  • Yokohama F Marinos: City Football Group offloads second club in space of six months

    Sport Business
    A diverse group of business professionals engaged in a dynamic discussion in a modern conference room setting
  • LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

    Business Wire
  • ‘Dispiriting’: Ministers speed up crackdown on Shein and Temu – by just six months

    Retail
    Shein clothing display showcasing latest fashion trends in a modern retail setting

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy